Clinical Trial Protocol Skill
AnthropicOfficialPublished by Anthropic
- Skill
- Workflow
- Science and research
- Apache-2.0
- Low risk
- Has scripts
AutoGineer summary
Written by AutoGineer from the skill’s own files, not by the author
This skill provides a structured, waypoint-based process to assist in the development of clinical trial protocols. It guides users through initializing an intervention, researching similar clinical trials via MCP tools, identifying relevant FDA regulatory pathways, and drafting protocol sections. The system uses a modular approach where each step is handled by a specific subskill, allowing for progress tracking and resumption of work.
What it does
- Collects and stores intervention metadata for medical devices or drugs.
- Searches clinical trial databases to identify similar studies and findings.
- Identifies relevant FDA regulatory pathways and guidance documents.
- Generates protocol sections covering foundation, design, population, and operations.
- Calculates statistical sample sizes using integrated Python scripts.
- Concatenates drafted sections into a final protocol document.
When to use it
- When you need to design a clinical study for a medical device or drug.
- When you are preparing documentation for FDA submissions.
- When you need to research existing clinical trials for a specific intervention.
- When you require a structured, step-by-step approach to drafting a clinical protocol.
Advantages
- Modular architecture allows for pausing and resuming work at any stage.
- Automated research using clinical trial databases and FDA resources.
- Maintains consistent state through JSON and markdown waypoint files.
- Supports the use of custom protocol templates.
- Includes built-in statistical tools for sample size calculations.
Usage examples
- “Create a clinical trial protocol for my new cardiac monitoring device.”
- The skill initializes the intervention, guides you through regulatory research, and begins drafting the protocol sections.
- “Research similar trials for a new diabetes drug.”
- The skill performs a search for relevant clinical trials and FDA guidance, providing a summary report.
Install
Download the skill as a ZIP:
https://autogineer.com/agent-skills/anthropics/clinical-trial-protocol-skill/downloadUnzip it into the cross-client skills folder of your project:
mkdir -p .agents/skills && unzip clinical-trial-protocol-skill.zip -d .agents/skills
Documentation by Anthropic
Clinical Trial Protocol Skill
⚠️ EXECUTION CONTROL - READ THIS FIRST
CRITICAL: This orchestrator follows a SIMPLE START approach:
Display the welcome message FIRST (shown in "Startup: Welcome and Confirmation" section below)
Ask user to confirm they're ready to proceed - Wait for confirmation (yes/no)
Jump directly into Full Workflow Logic - Automatically run subskills sequentially
Do NOT pre-read subskill files - Subskills are loaded on-demand only when their step executes
Why this matters:
Pre-reading all subskills wastes context and memory
Subskills should only load when actually needed during execution
Workflow automatically handles resuming from existing waypoints
Overview
This skill generates clinical trial protocols for medical devices or drugs using a modular, waypoint-based architecture
What This Skill Does
Starting with an intervention idea (device or drug), this orchestrated workflow offers two modes:
🔬 Research Only Mode (Steps 0-1): 0. Initialize Intervention - Collect device or drug information
Research Similar Protocols - Find similar trials, FDA guidance, and published protocols
Deliverable: Comprehensive research summary as formatted .md artifact
📄 Full Protocol Mode (Steps 0-5): 0. Initialize Intervention - Collect device or drug information
Research Similar Protocols - Find similar trials, FDA guidance, and published protocols
Protocol Foundation - Generate protocol sections 1-6 (foundation, design, population)
Protocol Intervention - Generate protocol sections 7-8 (intervention details)
Protocol Operations - Generate protocol sections 9-12 (assessments, statistics, operations)
Generate Protocol - Create professional file ready for stakeholder review
Architecture
Waypoint-Based Design
All analysis data is stored in waypoints/ directory as JSON/markdown files:
waypoints/
├── intervention_metadata.json # Intervention info, status, initial context
├── 01_clinical_research_summary.json # Similar trials, FDA guidance, recommendations
├── 02_protocol_foundation.md # Protocol sections 1-6 (Step 2)
├── 03_protocol_intervention.md # Protocol sections 7-8 (Step 3)
├── 04_protocol_operations.md # Protocol sections 9-12 (Step 4)
├── 02_protocol_draft.md # Complete protocol (concatenated in Step 4)
├── 02_protocol_metadata.json # Protocol metadata
└── 02_sample_size_calculation.json # Statistical sample size calculationRich Initial Context Support:
Users can provide substantial documentation, technical specifications, or research data when initializing the intervention (Step 0). This is preserved in intervention_metadata.json under the initial_context field. Later steps reference this context for more informed protocol development.
Modular Subskill Steps
Each step is an independent skill in references/ directory:
references/
├── 00-initialize-intervention.md # Collect device or drug information
├── 01-research-protocols.md # Clinical trials research and FDA guidance
├── 02-protocol-foundation.md # Protocol sections 1-6 (foundation, design, population)
├── 03-protocol-intervention.md # Protocol sections 7-8 (intervention details)
├── 04-protocol-operations.md # Protocol sections 9-12 (assessments, statistics, operations)
└── 05-generate-document.md # NIH Protocol generationUtility Scripts
scripts/
├── sample_size_calculator.py # Statistical power analysis
└── test_sample_size_calculator.py # Unit tests for the calculatorPrerequisites
1. clinical trials MCP Server (Required)
Installation:
Install via drag-and-drop
.mcpbfile into Claude DesktopOr configure manually in Claude Desktop settings
Available Tools:
search_clinical_trials - Search by:
condition - Disease or condition (e.g., "pancreatic cancer") intervention - Drug, device, or treatment (e.g., "pembrolizumab", "CAR-T") sponsor - Sponsor or collaborator name (e.g., "Pfizer", "NIH") location - City, state, or country (e.g., "California", "Boston") status - "recruiting" (default), "active", "completed", "all" phase - Trial phase: "1", "2", "3", "4", "early_phase1" max_results - Default 25, max 100
get_trial_details - Get comprehensive details for a specific trial using its nct_id (e.g., "NCT04267848"). Returns eligibility criteria, outcomes, study design, and contact information.
Verification: Step 1 will automatically test MCP connectivity at startup.
2. FDA Database Access (Built-in)
Purpose: FDA regulatory pathway research via explicit database URLs
Sources:
Step 1: FDA device/drug databases (510(k), PMA, De Novo, Drugs@FDA, Orange Book, Purple Book)
All sources use direct FDA database URLs - no generic web searches
3. Clinical Protocol Template
Template Files: Any .md files in the assets/ directory
Purpose: Reference template for protocol structure and content guidance. The system automatically detects available templates and uses them dynamically.
4. Python Dependencies (Required for Step 2)
Installation:
pip install -r requirements.txtDependencies:
scipy >= 1.11.0 (statistical calculations)
numpy >= 1.24.0 (numerical operations)
Purpose: Statistical sample size calculations for clinical protocols
How to Use
Simply invoke the skill and select your desired mode:
🔬 Research Only Mode:
Select "Research Only" from the main menu
Provide intervention information
Receive comprehensive research summary as formatted .md artifact
Option to continue with full protocol generation or exit
📄 Full Protocol Mode:
Select "Full Protocol" from the main menu
Guide you through all steps sequentially (Steps 0-5)
Pause after Step 4 to review the draft protocol
Generate the final protocol document when ready
Resume Capability: If interrupted, simply restart the skill and it will automatically resume from your last completed step.
Execution Flow
Startup: Welcome and Mode Selection
When skill is invoked, display the following message:
🧬 CLINICAL TRIAL PROTOCOL
Welcome! This skill generates clinical trial protocols for medical devices or drugs.
[If waypoints/intervention_metadata.json exists:]
✓ Found existing protocol in progress: [Intervention Name]
Type: [Device/Drug]
Completed: [List of completed steps]
Next: [Next step to execute]
📋 SELECT MODE:
1. 🔬 Research Only - Run clinical research analysis (Steps 0-1)
• Collect intervention information
• Research similar clinical trials
• Find FDA guidance and regulatory pathways
• Generate comprehensive research summary as .md artifact
2. 📄 Full Protocol - Generate complete clinical trial protocol (Steps 0-5)
• Everything in Research Only, plus:
• Generate all protocol sections
• Create professional protocol document
3. ❌ Exit
Please select an option (1, 2, or 3):🛑 STOP and WAIT for user selection (1, 2, or 3)
If 1 (Research Only): Set
execution_mode = "research_only"and proceed to Research Only Workflow LogicIf 2 (Full Protocol): Set
execution_mode = "full_protocol"and proceed to Full Workflow LogicIf 3 (Exit): Exit gracefully with "No problem! Restart the skill anytime to continue."
Research Only Workflow Logic
This workflow executes only Steps 0 and 1, then generates a formatted research summary artifact.
Step 1: Check for Existing Waypoints
If
waypoints/intervention_metadata.jsonexists: Load metadata, check if steps 0 and 1 are already completeIf no metadata exists: Start from Step 0
Step 2: Execute Research Steps (0 and 1)
For each step (0, 1):
Check completion status: If step already completed in metadata, skip with "✓ Step [X] already complete"
Execute step:
Display "▶ Executing Step [X]..."
Read and follow the corresponding subskill file instructions
Wait for completion
Display "✓ Step [X] complete"
Step execution method (ON-DEMAND LOADING): When a step is ready to execute (NOT before), read the subskill markdown file and execute ALL instructions within it
Step-to-file mapping:
Step 0:
references/00-initialize-intervention.md(collect intervention info)Step 1:
references/01-research-protocols.md(clinical research and FDA guidance)
Handle errors: If step fails, ask user to retry or exit. Save current state for resume capability.
Step 3: Generate Research Summary Artifact
After Step 1 completes successfully:
Read waypoint files:
waypoints/intervention_metadata.json(intervention details)waypoints/01_clinical_research_summary.json(research findings)
Create formatted markdown summary: Generate a comprehensive, well-formatted research summary as a markdown artifact with the following structure:
# Clinical Research Summary: [Intervention Name]
## Intervention Overview
- **Type:** [Device/Drug]
- **Indication:** [Target condition/disease]
- **Description:** [Brief intervention description]
- **Mechanism of Action:** [How it works]
## Similar Clinical Trials
[List top 5-10 similar trials with NCT ID, title, phase, status, key findings]
## FDA Regulatory Pathway
- **Recommended Pathway:** [510(k), PMA, De Novo, IND, NDA, BLA, etc.]
- **Regulatory Basis:** [Rationale for pathway selection]
- **Key Requirements:** [Major regulatory considerations]
## FDA Guidance Documents
[List relevant FDA guidance documents with links and key excerpts]
## Study Design Recommendations
- **Suggested Study Type:** [RCT, single-arm, etc.]
- **Phase Recommendation:** [Phase 1, 2, 3, etc.]
- **Primary Endpoint Suggestions:** [Based on similar trials]
- **Sample Size Considerations:** [Preliminary thoughts]
## Key Insights and Recommendations
[Synthesized recommendations for protocol development]
## Next Steps
[If user wants to proceed with full protocol development]
---
*Generated by Clinical Trial Protocol Skill*
*Date: [Current date]*Save artifact: Write the formatted summary to
waypoints/research_summary.mdDisplay completion message:
✅ RESEARCH COMPLETE
Research Summary Generated: waypoints/research_summary.md
📊 Key Findings:
• Similar Trials Found: [X trials]
• Recommended Pathway: [Pathway name]
• FDA Guidance Documents: [X documents identified]
• Study Design: [Recommended design]
📄 The research summary has been saved as a formatted markdown artifact.
Would you like to:
1. Continue with full protocol generation (steps 2-5)
2. Exit and review research summary
Option 1 Logic (Continue to Full Protocol):
Set
execution_mode = "full_protocol"Continue to Full Workflow Logic starting from Step 2 (since 0 and 1 are complete)
Option 2 Logic (Exit):
Display: "✓ Research summary saved. Restart the skill anytime to continue with protocol generation."
Exit orchestrator gracefully
Full Workflow Logic
Step 1: Check for Existing Waypoints
If
waypoints/intervention_metadata.jsonexists: Load metadata, checkcompleted_stepsarray, resume from next incomplete stepIf no metadata exists: Start from Step 0
Step 2: Execute Steps in Order
For each step (0, 1, 2, 3, 4, 5):
Check completion status: If step already completed in metadata, skip with "✓ Step [X] already complete"
Execute step: Display "▶ Executing Step [X]...", read and follow the corresponding subskill file instructions, wait for completion, display "✓ Step [X] complete"
Step execution method (ON-DEMAND LOADING): When a step is ready to execute (NOT before), read the subskill markdown file and execute ALL instructions within it
IMPORTANT: Do NOT read subskill files in advance. Only read them at the moment of execution.
Step-to-file mapping:
Step 0:
references/00-initialize-intervention.md(read when Step 0 executes)Step 1:
references/01-research-protocols.md(read when Step 1 executes)Step 2:
references/02-protocol-foundation.md(read when Step 2 executes - sections 1-6)Step 3:
references/03-protocol-intervention.md(read when Step 3 executes - sections 7-8)Step 4:
references/04-protocol-operations.md(read when Step 4 executes - sections 9-12)Step 5:
references/05-concatenate-protocol.md(read when Step 5 executes - final concatenation)
Handle errors: If step fails, ask user to retry or exit. Save current state for resume capability.
Display progress: "Progress: [X/6] steps complete", show estimated remaining time
Step 4 Completion Pause: After Step 4 completes, pause and display the Protocol Completion Menu (see below). Wait for user selection before proceeding.
Step 2.5: Protocol Completion Menu
After Step 4 completes successfully, display the EXACT menu below (do not improvise or create alternative options):
✅ PROTOCOL COMPLETE: Protocol Draft Generated
Protocol Details:
• Study Design: [Design from metadata]
• Sample Size: [N subjects from metadata]
• Primary Endpoint: [Endpoint from metadata]
• Study Duration: [Duration from metadata]
Protocol file: waypoints/02_protocol_draft.md
File size: [Size in KB]
📋 WHAT WOULD YOU LIKE TO DO NEXT?
1. 📄 Review Protocol in Artifact - click on the .md file above
2. 📄 Concatenate Final Protocol (Step 5)
3. ⏸️ Exit and Review Later
Option 1 Logic (Review in Artifact): Pause, let user open the section files, wait for further instruction
Option 2 Logic (Concatenate Protocol):
Execute Step 5 by reading and following
references/05-concatenate-protocol.mdStep 5 will concatenate all section files into final protocol document
Continue to Step 3 (Final Summary) after Step 5 completes
Option 3 Logic (Exit):
Display: "✓ Protocol sections saved. You can resume with Step 5 anytime to concatenate."
Exit orchestrator gracefully
Step 3: Final Summary
Display completion message with:
Intervention name, type (device/drug), indication
Protocol details (design, sample size, endpoints, duration)
All completed steps list
Final deliverable: Complete protocol markdown file location (waypoints/protocol_complete.md)
Waypoint files list for reference
Important disclaimers (FDA Pre-Sub, biostatistician review, IRB approval required)
Thank you message
Technical Details
Waypoint File Formats
JSON Waypoints (Steps 0, 1):
Structured data for programmatic access
Small file sizes (1-15KB)
Easy to parse and reference
Markdown Waypoints (Steps 2, 3, 4):
Step 2:
02_protocol_foundation.md(Sections 1-6)Step 3:
03_protocol_intervention.md(Sections 7-8)Step 4:
04_protocol_operations.md(Sections 9-12)Step 4:
02_protocol_draft.md(concatenated complete protocol)Human-readable protocol documents
Can be directly edited by users
Individual section files preserved for easier regeneration
Data Minimization Strategy
Each step implements aggressive summarization:
Keep: Top-N results (5-10 max)
Keep: Key facts and IDs (NCT numbers, endpoint types)
Keep: Concise rationale (2-3 sentences)
Discard: Raw MCP query results (not needed after analysis)
Discard: Full FDA guidance text (only excerpts/citations kept)
Discard: Lower-ranked search results
Step Independence
Each subskill is designed to:
Read only from waypoint files (not conversation history)
Produce complete output in single execution
Not depend on conversation context from previous steps
Be runnable standalone
Error Handling
MCP Server Unavailable
Detected in: Step 1
Action: Display error with installation instructions
Allow user to retry after installing MCP server
No fallback available - MCP server is required for protocol research
Step Fails or Returns Error
Action: Display error message from subskill
Ask user: "Retry step? (Yes/No)"
Yes: Re-run step
No: Save current state, exit orchestrator
User Interruption
All progress saved in waypoint files
User can resume anytime by restarting the skill
Workflow automatically detects completed steps and resumes from next step
No data loss
Disclaimers
⚠️ IMPORTANT: This protocol generation tool provides preliminary clinical study protocol based on NIH/FDA guidelines and similar trials. It does NOT constitute:
Official FDA or IRB determination or approval
Medical, legal, or regulatory advice
Substitute for professional biostatistician review
Substitute for FDA Pre-Submission meeting
Guarantee of regulatory or clinical success
REQUIRED before proceeding with clinical study:
Biostatistician review and sample size validation
FDA Pre-Submission meeting (Q-Submission for devices, Pre-IND for drugs)
IRB review and approval
Clinical expert and regulatory consultant engagement
Legal review of protocol and informed consent
Site investigator review and input
Sponsor completion of all [TBD] items in protocol
PROFESSIONAL CONSULTATION STRONGLY RECOMMENDED
Clinical trial protocols are complex, high-stakes documents requiring expertise across multiple disciplines. Professional consultation with clinical trial experts, biostatisticians, and regulatory affairs specialists is essential before proceeding with clinical study planning.
Implementation Requirements
When this skill is invoked:
Display the welcome message with mode selection (shown in "Startup: Welcome and Mode Selection" section)
Wait for user mode selection (1: Research Only, 2: Full Protocol, 3: Exit)
Execute based on selected mode:
Research Only Mode (Option 1):
Execute Research Only Workflow Logic (Steps 0-1 only)
Generate formatted research summary as .md artifact
Offer option to continue with full protocol or exit
Full Protocol Mode (Option 2):
Execute Full Workflow Logic (Steps 0-5)
Check for existing waypoints and resume from last completed step
OR start from Step 0 if no waypoints exist
Execute all steps sequentially until complete
For each step execution (LAZY LOADING - On-Demand Only):
ONLY when a step is ready to execute, read the corresponding subskill file
Do NOT read subskill files in advance or "to prepare"
Example: When Step 1 needs to run, THEN read
references/01-research-protocols.mdand follow its instructionsFor protocol development: Execute Steps 2, 3, 4 sequentially in order
Do NOT try to execute multiple steps in parallel - run sequentially
Read each step's subskill file only when that specific step is about to execute
Research summary artifact generation (Research Only Mode):
After Step 1 completes, read waypoint files
Generate comprehensive, well-formatted markdown summary
Save to
waypoints/research_summary.mdDisplay completion message with key findings
Handle errors gracefully:
If a step fails, give user option to retry or exit
If MCP server unavailable, explain how to install
All progress is saved automatically in waypoints
Track progress:
Update
waypoints/intervention_metadata.jsonafter each stepShow progress indicators to user (e.g., "Progress: 3/6 steps complete" or "Progress: 2/2 research steps complete")
Provide clear feedback on what's happening
Final output:
Research Only: Display research summary location and offer to continue with full protocol
Full Protocol: Congratulate user, display protocol location and next steps
Remind user of disclaimers
Files
- ATTRIBUTION.mdAdded by AutoGineer930 B
- LICENSE.txt10.0 KiB
- README.md2.9 KiB
- SKILL.md20.0 KiB
- assets/FDA-Clinical-Protocol-Template.md172.6 KiB
- references/00-initialize-intervention.md8.6 KiB
- references/01-research-protocols.md18.7 KiB
- references/02-protocol-foundation.md39.7 KiB
- references/03-protocol-intervention.md32.7 KiB
- references/04-protocol-operations.md82.4 KiB
- references/05-concatenate-protocol.md8.8 KiB
- scripts/sample_size_calculator.pyScript15.9 KiB
- scripts/test_sample_size_calculator.pyScript5.4 KiB
references/01-research-protocols.md
Step 1: Research Similar Clinical Protocols and Evidence
Purpose
Research similar clinical trials, FDA guidance documents, and published protocols to inform clinical protocol development.
Prerequisites
Required Files: waypoints/intervention_metadata.json
Required Tools: ClinicalTrials.gov MCP Server
Status Reporting Protocol
Always inform the user when performing regulatory research actions:
| Action | Format |
|---|---|
| Database Query | 🔍 Searching [DATABASE] for [terms]... |
| Document Review | 📄 Reviewing [TYPE]: [name/number]... |
| Regulation Lookup | 📋 Checking [CFR REF] for [purpose]... |
| Results Found | ✓ Found [N] results: [summary] |
| No Results | ⚠️ No direct matches. Expanding search to [alternative]... |
Example grouped output:
**Regulatory Database Research**
🔍 Searching Product Classification Database...
✓ Found: Product Code "GEX", Class II, 21 CFR 876.1500
🔍 Searching 510(k) Database for predicates...
✓ Found 12 cleared devices (filtering to top 5)
📄 Reviewing K201234 summary...Execution Flow
Step 1: Load Intervention Metadata
Read waypoints/intervention_metadata.json for: intervention name, type (device/drug/biologics), description, indication, target population, initial context, discovery clarifications.
Step 2: Device-Specific Regulatory Research
ONLY if intervention_type is "device".
Reporting: Inform the user when querying databases or reviewing documents.
<details open> <summary><b>FDA Device Regulations & Databases</b></summary>
</details>
Device Research Workflow
Step 2A.1: Device Classification
Query Product Classification Database for [device type from metadata].
Extract:
Device Class: I, II, or III
Product Code: (e.g., "GEX")
CFR Regulation: 21 CFR XXX.XXXX
Special Controls: (if Class II)
Device Name: Official classification name
Step 2A.2: Pathway Decision
IF Class III (high-risk): → Execute PMA Research Track (Step 2A.3a)
IF Class II (moderate-risk): → Execute 510(k) Research Track (Step 2A.3b) → IF no predicates found → Consider De Novo Track (Step 2A.3c)
IF Class I: → Check exemption status → IF exempt → Proceed to Step 3 (FDA Guidance Search) → IF not exempt → Execute 510(k) Research Track (Step 2A.3b)
Step 2A.3a: PMA Research Track (Class III Only)
Query PMA Database for [device type].
Extract from 3-5 approved PMAs:
PMA Number, Device Name, Manufacturer
Approval Date (prioritize recent approvals)
Clinical Trial Design: RCT, single-arm, sample size
Primary Endpoint & success criteria
Pivotal Study Requirements: Number of trials, duration
Post-approval Conditions: (if any)
Step 2A.3b: 510(k) Research Track (Class I/II with Predicates)
Query 510(k) Database for [device type].
Extract from 3-5 recent predicates (prioritize last 5-10 years, similar indication):
K-Number, Device Name, Manufacturer
Clearance Date
Indications for Use
Technological Characteristics: Design, materials, mechanism
Clinical Data: Required? Type? Sample size?
Testing Performed: Bench, animal, human studies?
Step 2A.3c: De Novo Research Track (Novel Device)
Query De Novo Database for [device type or similar mechanism].
Extract from relevant De Novo grants:
DEN Number, Device Name
Classification Decision: Class I or II determination
Special Controls Imposed: (if Class II)
Clinical Evidence Required: Study designs, sample sizes
Rationale: Why low-moderate risk determination made
Step 2A.4: IDE Risk Determination (All Pathways)
Assess Significant Risk (SR) vs Non-Significant Risk (NSR) per 21 CFR 812.3(m):
| Factor | Evaluation Question | SR Signal |
|---|---|---|
| Implanted? | Permanent, >30 days, or invasive implant? | Yes → SR |
| Life Support? | Sustains or supports life? | Yes → SR |
| Critical Diagnostic? | Substantial importance to diagnosis/treatment? | Yes → SR |
| Failure Risk? | Serious injury or death possible from failure? | Yes → SR |
| Precedent? | Similar devices classified as SR/NSR? | Match precedent |
Determination:
SR (Significant Risk) → Requires FDA IDE approval + IRB approval
NSR (Non-Significant Risk) → IRB approval only
Document: Rationale with specific 21 CFR 812.3(m) criteria cited and precedent analysis.
Step 2.2: Drug/Biologics-Specific Regulatory Research
ONLY if intervention_type is "drug" or "biologics".
Reporting: Inform the user when querying databases or reviewing documents.
<details open> <summary><b>FDA Drug/Biologics Regulations & Databases</b></summary>
</details>
Drug/Biologics Research Workflow
Step 2B.1: Drug Classification Assessment
Query Drugs@FDA and Orange Book for [drug name from metadata].
Determine:
Novelty: NCE (new chemical entity) vs previously approved moiety
Regulatory Status:
OTC vs Rx (21 CFR 330-358)
Controlled substance? (21 CFR 1308, Schedule I-V)
Product Type: Small molecule, biologic, biosimilar
Step 2B.2: Pathway Decision
IF Generic of approved drug: → Execute ANDA Research Track (Step 2B.3a)
IF Modified approved product (new dose/route/indication/formulation): → Execute 505(b)(2) Research Track (Step 2B.3b)
IF New Chemical Entity: → Execute NDA Research Track (Step 2B.3c)
IF Biologic: → Execute BLA Research Track (Step 2B.3d)
Step 2B.3a: ANDA Research Track (Generic Drug)
Query Orange Book for Reference Listed Drug (RLD).
Extract:
NDA Number, Drug Name
Active Ingredient(s): Name, strength
Dosage Form & Route: (e.g., tablet, oral)
Patent Information: Numbers, expiration dates
Exclusivity Expiration: Date when generic can be approved
TE Code: Therapeutic equivalence rating
Clinical Data Required: Bioequivalence (BE) studies only
Single-dose pharmacokinetic study
Steady-state PK study (if applicable)
No efficacy or safety trials needed (relies on RLD data)
Step 2B.3b: 505(b)(2) Research Track (Modified Product)
Query Drugs@FDA for similar approved products.
Extract from similar approvals:
Approval history for condition/indication
Changes from reference product that required new data
Bridging study designs used in precedent 505(b)(2) applications
Prior 505(b)(2) approvals for this type of modification
Clinical Data Required: Varies based on change
May leverage RLD safety/efficacy data for some aspects
Typically requires 1 pivotal trial + bridging studies
Examples: BA/BE studies, dose-ranging, PK in new population
Step 2B.3c: NDA Research Track (New Chemical Entity)
Query Drugs@FDA and ClinicalTrials.gov for condition/MOA precedents.
Extract from approved trials:
Phase 1/2/3 study designs for similar indications
Safety database size requirements (typically 1500+ patients for chronic use)
Number of pivotal trials required (typically 2 adequate & well-controlled Phase 3 trials)
Common primary/secondary endpoints for indication
Special population studies (pediatric, geriatric, renal/hepatic impairment)
Step 2B.3d: BLA Research Track (Biologics)
Query Purple Book and CBER guidance for biologic class.
Extract from approved biologics:
Similar biologics in therapeutic class
Immunogenicity assessment approaches used
Manufacturing/CMC complexity considerations
Biosimilar development pathways (if reference product exists)
Clinical Data Required: Similar to NDA
Potency assays critical for biologics
Immunogenicity monitoring throughout development
Manufacturing consistency demonstration
May require post-market safety studies (REMS)
Step 2B.4: IND Requirements (All Pathways)
Key Difference from Devices: IND required for ALL investigational drugs/biologics
No "NSR exemption" equivalent (unlike device IDE NSR)
Must submit IND before initiating Phase 1 clinical trials
30-day FDA review period before study start
Assess Clinical Hold Risk Factors per 21 CFR 312.42:
| Risk Factor | Evaluation Question | Hold Risk |
|---|---|---|
| Novel MOA? | Limited precedent for mechanism? | High if yes |
| Safety Signals? | Preclinical toxicology concerns? | High if unresolved |
| Tox Data? | Adequate animal studies for proposed dose/duration? | High if inadequate |
| CMC Concerns? | Manufacturing, stability, or quality issues? | High if present |
| High-Risk Population? | Vulnerable, pediatric, or critically ill patients? | Moderate-High |
| Study Design? | Unsafe dose escalation or inadequate monitoring? | High if unsafe |
Document:
IND submission strategy (Type A/B/C meeting needs)
Clinical hold risk mitigation plan
Relevant CFR citations (21 CFR 312 for IND)
ICH guideline compliance (E6-GCP, E9-Statistics, E10-Control Group)
Step 3: Search ClinicalTrials.gov for Similar Trials
Reporting: Inform the user when searching ClinicalTrials.gov and reviewing trial details.
Use ClinicalTrials.gov MCP Server:
| Tool | Parameters |
|---|---|
search_clinical_trials | condition, intervention, sponsor, location, status ("recruiting"/"active"/"completed"/"all"), phase ("1"/"2"/"3"/"4"), max_results (default 25, max 100) |
get_trial_details | nct_id (e.g., "NCT04267848") → eligibility, outcomes, design, contacts |
Extract: Study design (RCT, single-arm, crossover), phase, sample size, primary/secondary endpoints, duration, inclusion/exclusion criteria, comparator, status/results.
Step 4: Search for Published Protocols
Reporting: Inform the user when searching for published protocols.
CONSTRAINT: Use ONLY ClinicalTrials.gov MCP Server - Do not perform generic web searches.
Primary Source: ClinicalTrials.gov MCP Server (see Step 3 for MCP tool usage)
Use
get_trial_detailsto retrieve protocol documents for relevant NCT IDsExtract protocol PDFs when available through MCP interface
Extract: Protocol structure, endpoint definitions, inclusion/exclusion structure, statistical analysis plans, visit schedules, safety monitoring.
Step 5: Analyze and Summarize Findings
Synthesize into actionable insights:
| Category | What to Summarize |
|---|---|
| Study Design | Most common design, comparators, blinding, phases |
| Endpoints | Primary/secondary endpoints, measurement methods, timing |
| Sample Size | Range by phase/study type, powering considerations |
| Duration | Treatment period, follow-up, total duration |
| Population | Common inclusion/exclusion, age ranges, disease severity |
Step 6: Write Research Summary Waypoint
Create waypoints/01_clinical_research_summary.json with all findings.
Data Retention:
Keep: Top 5-10 similar trials (structured summary), key FDA regulatory pathway info from Step 2, design/endpoint recommendations
Discard: Full trial details beyond summary
Step 7: Display Summary
Create an artifact displaying Step 7 summary format (see below)
Display concise summary to user:
Steps taken and key findings
Regulatory pathway determination (from Step 2)
Clinical trial search results
Next steps for protocol development
STOP and ask the user: "Would you like me to proceed with the research step?"
Only continue to Step 2 if the user confirms
Output Files
| File | Size | Content |
|---|---|---|
waypoints/01_clinical_research_summary.json | ~10-15KB | Research findings |
waypoints/intervention_metadata.json | Updated | With regulatory info |
Quality Checks
All Interventions
[ ] At least 3-5 similar trials identified
[ ] Study designs appropriate for intervention type
[ ] Primary endpoint recommendations clear
[ ] Sample size considerations provided
[ ] FDA guidance relevant to intervention/indication
[ ] Duration recommendations realistic
[ ] Population criteria specific enough
Devices Only
[ ] Device classification (Class I/II/III)
[ ] Product code found
[ ] Regulatory pathway (510(k)/De Novo/PMA/Exempt)
[ ] Predicates identified (3-5 for 510(k)) OR De Novo/PMA precedents
[ ] Special Controls (if Class II)
[ ] IDE risk determination (SR/NSR) with rationale
[ ] Clinical data requirements understood
Drugs/Biologics Only
[ ] Classification (OTC/Rx, controlled schedule, NCE status)
[ ] Regulatory pathway (NDA/ANDA/505(b)(2)/BLA)
[ ] CFR references documented
[ ] Reference drug identified (ANDA/505(b)(2): Orange Book; BLA: Purple Book)
[ ] Clinical data requirements for pathway
[ ] IND requirements and clinical hold risks
[ ] ICH guideline requirements (E6, E9, E10)
[ ] Special population needs (pediatric, geriatric)
[ ] Manufacturing/CMC considerations (biologics)
Notes for Claude
Be thorough — protocol quality depends on good research
Always report status — user should see database queries and document reviews in real-time
Devices: Predicate devices are critical; classification determines pathway and requirements
Drugs/Biologics: Pathway determines everything; IND required for ALL (no NSR exemption); Orange Book and Purple Book are essential
NCE status affects exclusivity and data requirements
ICH guidelines are mandatory for protocol design
Requirements and compatibility
Written for: Claude Code, Claude apps
Works with: Claude Code, Claude apps, OpenAI Codex, GitHub Copilot, Cursor, Gemini CLI, Kiro, OpenCode, Goose, Amp, Roo Code, JetBrains Junie, Factory Droid, Devin (ex-Windsurf), Mistral Vibe, OpenHands, Letta
“Works with” means the tool reads the open Agent Skills format; a skill written for one tool may use features others lack.
Needs: Needs an MCP server, Needs Python
Security
What our scanner noticed· Low risk
- Instructions that use the network
- Scripts that your agent may run
This skill includes scripts that your agent may run. Read them before you use it.
A static scan is not a guarantee. Skills are third-party content: review a skill before you let an agent use it.
Attribution and licence
- Published by
- Anthropic
- Publisher
- Anthropic (Official)
- Source
- anthropics/life-sciences · clinical-trial-protocol-skill · commit 0d38fe5
- Licence
- Apache License 2.0 (redistribution allowed)
- ATTRIBUTION.md (written by AutoGineer)
- Synced
AutoGineer is not affiliated with or endorsed by Anthropic or Anthropic.
Download ZIP
The ZIP holds the skill’s files, its licence files and an ATTRIBUTION.md. Download clinical-trial-protocol-skill.zip